Page 4 - Laurus Labs
Laurus Labs Q2 profit up 14% at Rs 233 cr, revenue jumps to Rs 1,576 cr
Drug firm Laurus Labs on Friday said its consolidated net profit increased 14 per cent to Rs 233 crore in the second quarter ended September 30, 2022. The company had reported a net profit of Rs 204 crore in July-September period a year ago. Revenue from operations rose to Rs 1,576 crore in the quarter from Rs 1,203 crore in the year-ago period, Laurus Labs said in a statement. Laurus Labs Founder and CEO Satyanarayana Chava said the results reflect the company's efforts towards strengthening and diversifying its business. He noted that the company has developed a novel delivery for pediatric HIV treatment and expects to file an NDA (new drug application) shortly. "This should significantly enhance our market position. Our capital allocation priorities remain unchanged. We will continue to prioritise investments in our pipeline..," Chava stated. On business outlook, he said, "Looking forward to the second half of 2023, we expect to deliver a strong underlying revenue growth and s
 "Laurus Labs Q2 profit up 14% at Rs 233 cr, revenue jumps to Rs 1,576 cr")
Gene therapy to cure leukemia at one-tenth global costs in the works
ImmunoACT, backed by Laurus Labs is testing their cancer product
 "Gene therapy to cure leukemia at one-tenth global costs in the works")
Growth trajectory, margins anc client additions to sustain for Laurus Labs
Some of the growth is captured in the price rally, higher valuations
 "Growth trajectory, margins anc client additions to sustain for Laurus Labs")
Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%
The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.
 "Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%")
Laurus Labs surges 6% to hit over 4-month high
Analysts remain optimistic on the company's outlook for FY23 & FY24 with new capacity addition for commercial usage for FDF and API segments, ARV business and robust growth expected in CS business.
Laurus Labs up 8% in two days on purchase orders from global pharma company
The company on Thursday said it has received purchase orders from a leading global life sciences company and the supplies will commence from March 2022.
Laurus Labs bounces 16% from day's low on heavy volumes
The company said its Q3FY22 results were impacted by lower sales of ARV, APIs and formulations due to stocking at channel partners and it expects improvement from January-March quarter (Q4).
Buy these mid, smallcap stocks for at least 20% returns in 2022
Laurus Labs Ltd, Endurance Technologies Ltd may surge over 30 per cent whereas small cap stocks like Avanti Feeds Ltd, BASF India and Rain Industries could jump up to 40 per cent from current levels
 "Buy these mid, smallcap stocks for at least 20% returns in 2022")
Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT
Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the firm
Adani Transmission, Max Financials, Laurus Labs to gain from FTSE rejig
The three stocks are part of several other domestic companies likely to get added to FTSE indices. Adani Transmission is likely to see the largest inflows at $121 million
 "Adani Transmission, Max Financials, Laurus Labs to gain from FTSE rejig")
Laurus Labs hits record high; rallies 17% in 7 days post Q1 results
The management holds a positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio -- and believes the outlook remains robust driven by improving demand and supported by capex
 "Laurus Labs hits record high; rallies 17% in 7 days post Q1 results")
Laurus Labs rebounds 9% from day's low after 3 straight sessions of decline
The management maintains positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio-- on the back of improving demand, and supported by capacity expansion plans planned
Laurus Labs receives licence from DRDO to manufacture Covid drug 2DG
2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.
 "Laurus Labs receives licence from DRDO to manufacture Covid drug 2DG")
Prospects in key segments to keep Laurus Labs' growth trajectory strong
The stock has seen a six-fold jump in value over the last one year
 "Prospects in key segments to keep Laurus Labs' growth trajectory strong")
Laurus Labs rallies 5% on credit rating upgrade; stock hits record high
The company is looking to build new capacities/facilities that would propel its growth in the coming years
Laurus Labs gains 2% on robust growth outlook, zooms 70% so far in FY22
The company is looking to build new capacities and facilities that would propel its growth in the coming years
Laurus Labs, Alkyl Amines: More steam left after 1,000% gain from 2020 low?
Laurus Labs is likely to maintain its upward journey as long as it doesn't break the support level of Rs 600 levels
 "Laurus Labs, Alkyl Amines: More steam left after 1,000% gain from 2020 low?")
Laurus Labs trades higher for 8th straight day, soars 73% in 3 months
Shares of Laurus Labs continued their upward journey to hit a new high of Rs 599 on the BSE in intra-day trade on Tuesday
Laurus Labs shares advance 5% on strong growth outlook
Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model
 "Laurus Labs shares advance 5% on strong growth outlook")
Laurus Labs hits new high in subdued market, surges 30% in a month
The company is scheduled to meet on April 29, 2021, to consider and approve the audited financial results of the company for the financial year ended March 31, 2021
 "Laurus Labs hits new high in subdued market, surges 30% in a month")